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Background/aim: In this study, we investigated the effectiveness of antibiotic prophylaxis (ABP) with respect to the incidence of
symptomatic urinary tract infections (UTIs) and evaluated the development of renal scarring in patients treated with clean intermittent
catheterization (CIC).
Materials and methods: A total of 22 patients were included in the study. The patients were administered ABP in the first year (the
ABP-received period) but not in the second year (the ABP-discontinued period).
Results: Twenty-eight of all cultures taken in the ABP-received period (18.2%) and 25 (16.2%) of the ABP-discontinued cultures were
considered to be indicative of symptomatic UTIs (P = 0.65). The multiple antibiotic resistance rate of microorganisms in cultures taken
during the ABP-discontinued period (47; 30.5%) was lower than that in those taken in the ABP-received period (62; 40.3%), (P = 0.07).
There was no difference between the ABP-received and ABP-discontinued periods with respect to the development of new lesions
according to dimercaptosuccinic acid results (P = 0.14).
Conclusion: Routine ABP usage is not protective against the development of symptomatic UTIs and new lesions in neurogenic bladder
patients receiving CIC. Furthermore, the growth of resistant microorganisms increased in the ABP-received period.
Key words: Clean intermittent catheterization, neurogenic bladder, urinary tract infection

1. Introduction
Neurogenic bladder (NB) refers to the deterioration of
bladder function and the inconvenient retention and/or
discharge of urine as a result of cerebral cortex, medulla
spinalis, or peripheral nervous system lesions. Although
the causes of this condition are usually congenital, it may
also be acquired (1).
Disruption of coordination between the detrusor
and sphincter muscles leads to various pathophysiologic
conditions in NB. Lack of coordination between the
detrusor and sphincter muscles gives rise to high intravesical
pressure and urine retention. This can be associated with
the vesicoureteral reflux (VUR). The combination of high
intravesical pressure, urine retention, and VUR may result
in pyelonephritis and renal scar formation, which, in turn,
can lead to loss of renal function (1,2).
The suggested treatment for NB patients without
appropriate bladder emptying is clean intermittent
catheterization (CIC), which involves emptying the bladder
at regular intervals using a sterile catheter. The incidence
of urinary tract infections and/or bacteriuria may be
* Correspondence: ipekozunan@yahoo.com

elevated in children with NB, because of contamination
and inflammation resulting from catheterization
and urine retention. There are various reports in
the literature concerning prophylactic antibacterial
treatment administration in children with NB. Despite
the fact that long-term antibacterial prophylaxis (ABP)
increases bacterial resistance and therefore leads to
resistant infections, some groups continue to assert
that this treatment is necessary (3). Multiple-drug
resistance (MDR) is a condition that enables diseasecausing microorganisms to resist distinct antimicrobials,
first and foremost antibiotics (4).
In this study, we investigated the effectiveness of ABP
with respect to the incidence of symptomatic urinary tract
infections and evaluated the development of renal scarring
in patients treated with CIC.
2. Materials and methods
Twenty-two patients who were admitted to the Celal Bayar
University Hafsa Sultan Hospital Pediatric Nephrology
Polyclinic with NB secondary to neural tube defects and
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who were being treated with CIC were included in the
study. All patients were monitored for 1 year while they
received ABP (prophylaxis consisting of amoxicillin
for infants, trimethoprim/sulfamethoxazole, and, if
resistance occurred, nitrofurantoin) and for an additional
year after termination of prophylactic treatment. All
symptomatic infections were treated according to
routine protocols. Empirical treatment was given to
patients with symptomatic reproduction (cefuroxime,
ceftriaxone, ampicillin, amoxicillin clavulanate, cefixime,
aminoglycoside, imipenem, etc.).
Urinary ultrasonography, dimercaptosuccinic acid
(DMSA), and voiding cystourethrogram (VCUG)
findings were evaluated in both the ABP-received and
ABP-discontinued periods. Routine urine analysis and
urinary cultures were performed at 3-month intervals.
During symptomatic urinary tract infections (UTIs),
urine analysis, urinary cultures, and acute-phase reactant
analyses were also performed. An infection was defined as
the presence of ≥105 colonies of the same microorganism
in the urine sample taken by catheter. Symptomatic
infections recorded in both periods involving nausea,
vomiting, abdominal pain, high fever, and cloudy and foul
smelling urine were prospectively evaluated along with
the resistance patterns of microorganisms. Development
of new lesions was evaluated prospectively by DMSA.
We obtained informed consent from all patients or their
families for the study.
2.1. Statistical analysis
SPSS 15.0 for Windows was used for statistical analysis.
Data (numbers, percentage distributions, means, standard
deviations) were evaluated using Fisher’s exact test, the
chi-square test for binary and multivariate data, and
the Mann–Whitney U test with Spearman’s correlation
coefficient.

3. Results
The mean age of patients was 12.9 years (7–19 years); 15
patients were female and 7 were male. The most common
uropathogen in both periods was Escherichia coli (in all
cultures incidence of E. coli was 37.3%, with 26% of them
extended spectrum beta-lactamase+). The other pathogens
observed at decreasing frequency were Enterobacteriaceae,
Klebsiella, Pseudomonas, etc. Colonization was observed in
48 of the routine urine cultures (54.5%) taken in the ABPreceived period and in 44 cultures (50%) taken in the ABPdiscontinued period (P = 0.54). Of all the urine cultures
taken in the ABP-received and ABP-discontinued periods,
28 (18.2%) and 25 (16.2%) were consistent with the presence
of a UTI (symptomatic), respectively. More UTIs occurred
in the ABP-received period than in the ABP-discontinued
period, but this difference was not statistically significant
(P = 0.65, Table 1). Although the frequency of multiple
antibiotic resistance in routine cultures taken in the ABPreceived period (62; 40.3%) was greater than that in the
ABP-discontinued period (47; 30.5%), the difference was
not statistically significant (P = 0.07). Multiple-antibiotic
resistance included ampicillin, amoxicillin-clavulanate,
ampicillin-sulbactam, trimethoprim/sulfamethoxazole,
gentamicin, nitrofurantoin, cefuroxime, cefazolin,
cefoxitin, ceftazidime, and ceftriaxone (Table 2).
Six of the patients with hypoactive lesions in the
baseline DMSA scan had renal scar formation after ABP
(1st year). After the discontinuation of ABP, one patient’s
scar was regressed, and two patients had new lesions in
DMSA studies. There was no difference between the
DMSA findings of patients during the ABP-received and
ABP-discontinued periods, as in both periods two patients
developed new lesions (P = 0.14). The incidence of VUR in
the study sample was 9.1% (n = 2 patients). No significant
differences were found between groups with respect to the
urodynamic patterns analyzed in an attempt to identify

Table 1. Symptomatic UTIs and resistance development.
In all cultures

Prophylaxis (+) (n = 66)

Prophylaxis (-) (n = 88)

P

Routine culture colonization

48 (54.5%)

44 (50.0%)

0.54

Routine culture symptomatic colonization

16 (33.3%)

16 (36.4%)

0.09

Total symptomatic colonization

28 (18.2%)

26 (16.2%)

0.65

Pyuria (+)

67 (43.5%)

67 (43.5%)

1.00

Nitrite (+)

44 (28.5%)

38 (24.6%)

0.43

Multiple-antibiotic resistance development

62 (40.4%)

47 (30.5%)

0.07

Total routine culture number in prophylaxis = 88, total routine culture number in without-prophylaxis period = 88.
Total culture number in prophylaxis = 154, total culture number in without-prophylaxis period = 154. Total culture
number in 2 years = 308.
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factors playing a role in the development of new lesions or
UTIs. Other than three patients, all patients had detrusor
hyperreflexia-sphincter hyperreflexia, and three patients
had detrusor areflexia-sphincter hyperreflexia.
4. Discussion
Scarring of the upper urinary tract occurs in approximately
63% of children who do not receive appropriate treatment
within the first 3 years of developing NB. It has been
shown that scarring can be reduced by up to 50% with
appropriate early treatment (1). The most important risk
factors for upper urinary tract scar formation are detrusorsphincter dyssynergia, reduced bladder compliance, and a
filling pressure exceeding 40 cmH2O (1,2). Pyelonephritis
attacks also significantly increase the risk of renal scarring.
The reduction of intravesical pressure by CIC plays an
important role in early phases of treatment.
The periurethral region of children treated with CIC is
thought to be colonized with microorganisms arising from
the gastrointestinal system. Although bacteriuria is common
(30%–70%) in these cases, the UTI risk rate (20%–40%) is less
than expected (1). Whereas CIC may result in contamination
of the bladder with bacteria from the periurethral region,
it may also reduce the risk of infection through continuous
discharge of residual urine. In this sense, CIC can sterilize
a chronically infected bladder (5–7). Furthermore, CIC
management reduces renal scarring in children with VUR
by effectively reducing intravesical pressure. Reflux incidence
decreased by 30%–50% in children with NB in the 2–3 years
after CIC treatment as a result of reducing bladder filling and
emptying pressures (1).

We did not find any beneficial effect of ABP in this study.
Clarke et al. classified 85 cases of NB patients receiving
CIC into two groups: those taking prophylactic antibiotics
and those who had discontinued the use of prophylactic
antibiotics. When comparing the UTI occurrence during
a 4-month period, this group reported that UTI incidence
was significantly higher in the group taking prophylactic
antibiotics compared with that in the discontinued group.
Therefore, they concluded that sustained antibiotic
prophylaxis was unnecessary in patients receiving CIC (5).
Schlager et al. studied the effect of nitrofurantoin prophylaxis
on symptomatic UTIs and bacteriuria and found that
nitrofurantoin was not effective for bacteriuria eradication
in a double-blind, placebo-controlled, randomized study that
included 15 children with NB treated with CIC in 1998. It
was suggested that antibiotics used for prophylaxis might
cause increased infection risk by increasing the antibacterial
resistance of microorganisms (8). Although the incidence
of UTI was higher in the ABP-received period, there was
no statistically significant difference between the groups.
The multiple-antibiotic resistance frequency of the ABPdiscontinued period was lower than that of the ABP period,
but this was not found to be statistically significant.
Infections seen in NB cases may cause upper urinary
tract scarring, especially in children with VUR and/or
high intravesical pressure, depending on the virulence
of the microorganism involved. DMSA is an important
screening method used in scanning for pyelonephritis in
the acute phase and renal scarring in the chronic phase.
A comparison of DMSA findings at the time of initial
diagnosis, during the prophylaxis period, and after

Table 2. The antibiotic resistance patterns for each antibiotic in both periods and their statistical differences.
Prophylaxis (+)
(n = 66)

Prophylaxis (-)
(n = 88)

Resistant %

Resistant %

Ampicillin

24.2

36.3

0.10

Ampicillin sulbactam

9.0

4.5

0.25

Amoxicillin

-

4.5

0.07

Amoxicillin clavulanate

10.6

10.2

0.93

Cefazolin

7.5

5.6

0.63

Cefuroxime

7.5

14.7

0.16

Cefaclor

3.0

2.2

0.76

Ceftriaxone

7.5

10.2

0.59

Cefotaxime

-

1.1

0.57

Ceftazidime

1.5

2.2

0.73

Gentamicin

4.5

5.6

0.75

Trimethoprim sulfamethoxazole

6.0

14.7

0.09

Nitrofurantoin

-

3.4

0.18

Antibiotics

P
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prophylaxis cessation found that the percentage functions
were similar and no statistically significant differences were
detected; however, 6 patients developed renal scarring and
2 patients developed new lesions.
In NB cases with hydronephrosis, the existence of
VUR is evaluated by performing VCUG. The incidence of
VUR can increase up to 50% in patients with functional
bladder outlet obstruction (1). VUR incidence was found
to be 9.1% (n = 2 patients) in this study.
No significant differences were found between the
ABP-received and ABP-discontinued groups with respect
to the urodynamic patterns analyzed in an attempt to
identify factors playing a role in the development of new
lesions or UTIs. The most common urodynamic pathology
was observed to be detrusor sphincter dyssynergia.
Antibacterial prophylaxis for NB and VUR has
become controversial in recent years, but approaches
to the prevention of recurrent UTIs have changed since
2006 in response to the results of randomized controlled
studies. Today, routine antibiotic prophylaxis in children
with VUR is not suggested in the UTI guidelines (9,10).
Six important studies showed no benefit of antibiotic
prophylaxis compared with a placebo, even in high-grade
VUR (11). The aim of prophylaxis in children with VUR
is to prevent recurrences of symptomatic UTIs and renal
scarring. A metaanalysis of 11 randomized controlled
studies consisting of a total of 2046 children revealed that
antibiotic prophylaxis had no effect on renal scar formation
or healing, although it did reduce the recurrence of

symptomatic UTIs and the rate of positive urine cultures.
Furthermore, bacterial resistance and severe adverse
effects were reported in many studies (12).
Another 2-year multisite, randomized, placebocontrolled study evaluating 607 children with VUR
and a first or second febrile UTI examined the effect
of trimethoprim/sulfamethoxazole prophylaxis for
preventing UTI recurrence, renal scar formation,
treatment failure, and antimicrobial resistance. At the
end of study, no difference was seen between groups with
respect to renal scar formation, but the recurrence rate
was reduced in response to antibiotic prophylaxis (13).
Although the frequency with which multiple-antibiotic
resistance was observed in all cultures taken in the
antibiotic-discontinuation period was lower than that in
the prophylaxis period, this difference was not statistically
significant. According to the DMSA data, there were no
significant differences between the two periods with
respect to the formation of new lesions. Our study did not
include a sufficient number of cases of NB with VUR to
permit observations regarding this matter.
In this study, we revealed that routine ABP usage in
NB cases treated with CIC has no protective effect on
the development of symptomatic UTIs and new lesions
according to DMSA results. Furthermore, more resistant
colonies were observed in the ABP-received period. A
limiting aspect of this study was the small number of
patients. However, we would like to conclude that routine
ABP usage is not necessary under these circumstances.
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